Santen Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Santen Pharmaceutical ha un patrimonio netto totale di ¥288.3B e un debito totale di ¥0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente ¥409.1B e ¥120.8B. L'EBIT di Santen Pharmaceutical è ¥51.0B rendendo il suo rapporto di copertura degli interessi 333.1. Ha liquidità e investimenti a breve termine pari a ¥84.4B.

Informazioni chiave

Rapporto debito/patrimonio netto

JP¥0

Debito

Indice di copertura degli interessi	333.1x
Contanti	JP¥84.44b
Patrimonio netto	JP¥288.25b
Totale passività	JP¥120.83b
Totale attività	JP¥409.09b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Nov 18

Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next

Nov 11

Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk

Oct 14

Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)

Aug 31

Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 08

Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Jun 25

Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

May 11

Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?

May 08

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥218.5B ) di 4536 superano le sue passività a breve termine ( ¥83.9B ).

Passività a lungo termine: Le attività a breve termine di 4536 ( ¥218.5B ) superano le sue passività a lungo termine ( ¥37.0B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4536 è esente da debiti.

Riduzione del debito: 4536 non aveva debiti 5 anni fa.

Copertura del debito: 4536 non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: 4536 non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.

Santen Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.

Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk

Upcoming dividend of JP¥17.00 per share

Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024

Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)

Now 20% undervalued

Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

Final dividend of JP¥17.00 announced

New minor risk - Earnings quality

High number of new directors

Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024

Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2024 earnings: EPS misses analyst expectations

Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.

Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?

Upcoming dividend of JP¥17.00 per share

Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024

Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024

Now 21% undervalued

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.5% to JP¥1,533

Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024

Upcoming dividend of JP¥16.00 per share at 2.3% yield

Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Santen Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024

Upcoming dividend of JP¥16.00 per share at 2.9% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023

Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 13,000,000 shares, representing 3.35% for ¥13,000 million.

Upcoming dividend of JP¥16.00 per share

Santen Pharmaceutical Co., Ltd. Announces Executive Changes

Santen Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Santen Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Santen Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 04, 2022

Price target decreased to JP¥1,302

Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to JP¥1,532

Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022

Upcoming dividend of JP¥16.00 per share

Third quarter 2022 earnings: EPS misses analyst expectations

Santen Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year-Ending of March 2022

Second quarter 2022 earnings released: EPS JP¥17.33 (vs JP¥19.09 in 2Q 2021)

Upcoming dividend of JP¥16.00 per share

First quarter 2022 earnings released: EPS JP¥18.47 (vs JP¥15.49 in 1Q 2021)

High number of new directors

Price target decreased to JP¥1,679

Full year 2021 earnings released: EPS JP¥17.10 (vs JP¥59.17 in FY 2020)

Santen Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 2022

Consensus forecasts updated

Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended March 31, 2021

Upcoming dividend of JP¥14.00 per share

Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

New 90-day low: JP¥1,616

Third quarter 2021 earnings released: EPS JP¥18.29 (vs JP¥17.91 in 3Q 2020)

Revenue and earnings beat expectations